TY - JOUR
T1 - Proteasome inhibitor MG132 inhibits angiogenesis in pancreatic cancer by blocking nf-κb activity
AU - Matsuo, Yoichi
AU - Sawai, Hirozumi
AU - Ochi, Nobuo
AU - Yasuda, Akira
AU - Sakamoto, Masaki
AU - Takahashi, Hiroki
AU - Funahashi, Hitoshi
AU - Takeyama, Hiromitsu
AU - Guha, Sushovan
N1 - Funding Information:
Acknowledgments The authors would like to thank Karen Phillips from the Department of Scientific Publications for carefully reviewing this manuscript. This research was supported in part by The University of Texas M.D. Anderson Cancer Center Physician Scientist Program Award (to SG) and NIH grant CA16672 (Cancer Center Support Grant to M.D. Anderson Cancer Center).
PY - 2010/4
Y1 - 2010/4
N2 - Since angiogenesis enables solid tumors, including pancreatic cancer (PaCa), to grow and metastasize, the development of anti-angiogenic agents is currently one of the urgent issues. Proteasome inhibitors are well known for inhibiting nuclear factor-kappa B (NF-κB) activity in various cancer cells, but little is known about their biologic mechanisms against angiogenesis in PaCa. We divided human PaCa cell lines into high-angiogenic (BxPC-3 and SW 1990) and low-angiogenic (MIA PaCa-2 and Capan-2) groups. The high-angiogenic PaCa cell lines constitutively expressed high NF-κB activity and produced high levels of vascular endothelial growth factor (VEGF) and interleukin 8 (IL-8). The conditioned media from BxPC-3 significantly enhanced both proliferation of and tube formation by human umbilical vein endothelial cells (HUVECs) and these enhancements were significantly inhibited by the proteasome inhibitor MG132 treatment. Collectively, MG132 blocked PaCa-derived VEGF and IL-8 production through inhibition of NF-κB activity. Thus, proteasome inhibitors may prove beneficial as anti-angiogenic therapy for PaCa. Our studies show that MG132, a proteasome inhibitor, significantly blocked pancreatic-cancer-associated angiogenesis through inhibition of NF-κB and NF-κB-dependent proangiogenic gene products VEGF and IL-8.
AB - Since angiogenesis enables solid tumors, including pancreatic cancer (PaCa), to grow and metastasize, the development of anti-angiogenic agents is currently one of the urgent issues. Proteasome inhibitors are well known for inhibiting nuclear factor-kappa B (NF-κB) activity in various cancer cells, but little is known about their biologic mechanisms against angiogenesis in PaCa. We divided human PaCa cell lines into high-angiogenic (BxPC-3 and SW 1990) and low-angiogenic (MIA PaCa-2 and Capan-2) groups. The high-angiogenic PaCa cell lines constitutively expressed high NF-κB activity and produced high levels of vascular endothelial growth factor (VEGF) and interleukin 8 (IL-8). The conditioned media from BxPC-3 significantly enhanced both proliferation of and tube formation by human umbilical vein endothelial cells (HUVECs) and these enhancements were significantly inhibited by the proteasome inhibitor MG132 treatment. Collectively, MG132 blocked PaCa-derived VEGF and IL-8 production through inhibition of NF-κB activity. Thus, proteasome inhibitors may prove beneficial as anti-angiogenic therapy for PaCa. Our studies show that MG132, a proteasome inhibitor, significantly blocked pancreatic-cancer-associated angiogenesis through inhibition of NF-κB and NF-κB-dependent proangiogenic gene products VEGF and IL-8.
UR - http://www.scopus.com/inward/record.url?scp=77950356821&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77950356821&partnerID=8YFLogxK
U2 - 10.1007/s10620-009-0814-4
DO - 10.1007/s10620-009-0814-4
M3 - Article
C2 - 19399612
AN - SCOPUS:77950356821
SN - 0163-2116
VL - 55
SP - 1167
EP - 1176
JO - Digestive Diseases and Sciences
JF - Digestive Diseases and Sciences
IS - 4
ER -
